Merck & Company, Inc. which can be found using ticker (MRK) have now 24 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The target price High/Low ranges between 135 and 96 calculating the average target price we see $118.96. Given that the stocks previous close was at $113.75 and the analysts are correct then we can expect a percentage increase in value of 4.6%. It’s also worth noting that there is a 50 day moving average of $107.81 and the 200 moving average now moves to $100.09. The company has a market cap of $293,306m. Visit the company website at: https://www.merck.com
The potential market cap would be $306,740m based on the market consensus.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
The company has a dividend yield of 2.53% with the ex dividend date set at 14-3-2023 (DMY).
Other points of data to note are a P/E ratio of 20.24, revenue per share of 23.41 and a 11.96% return on assets.
